Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anxiety; Generalized Clear all
Completed Phase 3 Interventional

A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

NCT00236054
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Gabitril
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 4 Interventional

Chamomile Therapy for Generalized Anxiety

NCT00645983
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Chamomile Extract, Placebo
Dietary Supplement · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

NCT01470469
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
Interventions
SPD503 (extended-release Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Birmingham, Alabama • Carson, California • Imperial, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

NCT00715039
View directory record Official record
Conditions
Anxiety Disorders
Interventions
lorazepam, placebo, paroxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Glendale, California • Northridge, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2008 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Parent-based Treatment for Youth With Anxiety and Obsessive-compulsive Disorder

NCT04922502
View directory record Official record
Conditions
Obsessive-Compulsive Disorder in Children, Social Anxiety Disorder of Childhood, Obsessive-Compulsive Disorder in Adolescence, Separation Anxiety, Generalized Anxiety Disorder, Panic Disorder, Panic Attacks, Panic With Agoraphobia
Interventions
Standard SPACE, Bibliotherapy, low therapist contact SPACE
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Electronic Self-management Resource Training for Mental Health

NCT01304862
View directory record Official record
Conditions
Depression, Generalized Anxiety Disorder
Interventions
eSMART-MH intervention, Educational videos about healthy living
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 26, 2026, 9:08 AM EDT
Terminated Phase 4 Interventional Results available

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

NCT00374543
View directory record Official record
Conditions
Generalized Anxiety Disorder, Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Efficacy of Adding Interpersonal and Emotional Processing Therapy Techniques to Cognitive Behavioral Therapy to Treat Generalized Anxiety Disorder

NCT00951652
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
CBT, Interpersonal and emotional processing therapy, supportive listening
Behavioral · Other
Lead sponsor
Michelle G. Newman
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 26, 2026, 9:08 AM EDT
Terminated Phase 3 Interventional

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

NCT00658372
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
29
States / cities
Arcadia, California • Costa Mesa, California • Escondido, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 26, 2026, 9:08 AM EDT
Terminated Phase 3 Interventional

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

NCT00735267
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
93
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Arcadia, California + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

NCT00662259
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Alprazolam (Xanax), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Sep 26, 2026, 9:08 AM EDT
Withdrawn Not applicable Interventional

Assessing Different Methods of Anxiety Care in Pediatric Settings

NCT00769925
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Cognitive Behavior Therapy-Primary Care, Therapist-Assisted Bibliotherapy-Primary Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
8 Years to 13 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Sep 26, 2026, 9:08 AM EDT
Withdrawn Not applicable Interventional

Worry Exposure for Generalized Anxiety Disorder

NCT02382224
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Worry Exposure for GAD, 12-week Waitlist
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 26, 2026, 9:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

NCT00800280
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, cimetidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 3 Interventional

A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

NCT00236015
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Gabitril
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 64 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Mesa, Arizona • Peoria, Arizona • El Centro, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 26, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional

Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety

NCT05427708
View directory record Official record
Conditions
Anxiety Disorders, Trauma, Generalized Anxiety Disorder, Panic Disorder, Agoraphobia, Illness Anxiety Disorder, Social Anxiety Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Adjustment Disorder With Anxious Mood
Interventions
Capnometry-Guided Respiratory Intervention, Psycho-Education
Device · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD

NCT04111874
View directory record Official record
Conditions
Cognitive Behavioral Therapy, Autism Spectrum Disorder, Anxiety Disorders, Obsessive-Compulsive Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder, Specific Phobia
Interventions
Cognitive Behavioral Teletherapy LTA, Cognitive Behavioral Teletherapy STA
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 13 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 3 Interventional

Duloxetine vs Placebo in the Treatment of General Anxiety

NCT00475969
View directory record Official record
Conditions
Anxiety
Interventions
duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2007 · Synced Sep 26, 2026, 9:08 AM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder

NCT00252343
View directory record Official record
Conditions
Anxiety Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

NCT00481325
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
pexacerfont, escitalopram, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Mesa, Arizona • Burbank, California • Costa Mesa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults With Dementia

NCT04338750
View directory record Official record
Conditions
Anxiety, Anxiety Generalized, Anxiety Disorders and Symptoms, Caregiver Burnout
Interventions
Telephone Acceptance and Commitment Therapy Intervention for Caregivers, minimally-Enhanced Usual Care
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 26, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

NCT03924323
View directory record Official record
Conditions
Anxiety Disorders,Generalized Anxiety Disorder
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
7 Years to 17 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
39
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 26, 2026, 9:08 AM EDT